The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer

John Vitarello1,*, Marcus D. Goncalves2, Qin C. Zhou3, Alexia Iasonos3, Darragh F. Halpenny4, Andrew Plodkowski4, Emily Schwitzer5, Jennifer J. Mueller6,7, Oliver Zivanovic6,7, Lee W. Jones6, Karen A. Cadoo1, Jason A. Konner1
1Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA,
2Division of Endocrinology, Department of Medicine, Weill Cornell Medicine, New York, NY, USA,
3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA,
4Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA,
5Cardiology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA,
6Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA,
7Department of Obstetrics and Gynecology, Weill Cornell Medical Center, New York, NY, USA

Abstract

Background—The aim of this study was to quantify changes in body composition during ovarian cancer treatment and relate these changes to rates of complete gross resection (CGR).

Methods—One hundred two patients with stage III or IV ovarian cancer who underwent neoadjuvant chemotherapy (NACT) followed by interval debulking surgery were a part of a prospectively collected database that included computed tomography scans at three time points—diagnosis, following NACT, and following debulking surgery. Skeletal muscle, visceral adipose, and subcutaneous adipose tissue volumes were obtained from a 30-mm volumetric slab beginning at the third lumbar vertebrae.

Results—Following NACT, skeletal muscle volume was significantly reduced (352.5 to 335.0 cm³, P < 0.001), whereas adiposity was unchanged. Body mass index (BMI) and skeletal muscle volume were significantly lower in patients who achieved CGR (P < 0.05). When these patients

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

*Correspondence to: John Vitarello MD, Resident Physician, Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. Phone: (301) 514-4806, jvitarello@bidmc.harvard.edu.

Online supplementary material
Additional supporting information may be found online in the Supporting Information section at the end of the article.

Conflict of interest
The authors declare no conflicts of interest.
were stratified by BMI, the significant association of skeletal muscle to CGR was limited to patients with a BMI < 25 kg/m\(^2\) (\(P = 0.007\)).

**Conclusion**—Skeletal muscle volume was significantly reduced in patients undergoing NACT for ovarian cancer. Non-overweight patients were more likely to achieve CGR if they had lower skeletal muscle volume. Use of volumetric-based measurement for ascertaining body composition should be explored further.

**Introduction**

Ovarian cancer is the leading cause of death in women with gynaecological cancer.\(^1\) The standard approach to treatment is primary debulking surgery followed by platinum-based and taxane chemotherapy in women who are eligible for surgery. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery is an alternative to primary debulking surgery in patients who are not eligible for upfront surgery or in whom suboptimal debulking is expected due to the extent of disease. Two randomized trials reported similar survival rates among patients treated with NACT vs. primary debulking surgery followed by chemotherapy; however, survival in both arms of these studies was poorer than expected.\(^2,3\) Additional trials are ongoing.

Obesity is thought of as a trigger for the development of ovarian cancer. For example, multiple cohort studies have demonstrated an association between ovarian cancer mortality and obesity, as measured by body mass index (BMI).\(^4,5\) One study found that the relative risk of death increased 7% for each 5% increase in BMI.\(^6\) This increased risk likely stems from physiologic changes resulting from excess adiposity, a clinical feature that typically correlates with BMI.\(^7-10\) BMI, however, may not accurately reflect whole body adiposity in patients with ovarian cancer because of the changes that occur in total body water, such as ascites or oedema. Therefore, it is not surprising that some groups have found no change in survival when examining BMI at the time of diagnosis.\(^11-13\) A more accurate measurement of adiposity can be obtained using computed tomography (CT) from standard of care imaging.\(^14-16\) This technique has shown that weight gain following debulking surgery is primarily body fat and that loss of skeletal muscle, as measured by sequential CT scans, is associated with decreased survival in ovarian cancer patients.\(^17,18\)

The aim of the current study was to investigate changes in body composition, including changes in skeletal muscle, subcutaneous adipose tissue (SAT), and visceral adipose tissue (VAT) volumes, in ovarian cancer patients receiving NACT. Achieving surgical complete gross resection (CGR) is regarded as the most important prognostic factor in patients with advanced ovarian cancer\(^3,19,20;\) therefore, we attempted to identify clinical and body composition parameters that are enriched in patients achieving CGR. Moreover, loss of skeletal muscle has been shown to be an independent prognostic factor in other cancers.\(^21\)

**Methods**

**Patients and setting**

This is a retrospective analysis of prospectively collected clinical data and imaging parameters of a cohort of patients with a diagnosis of epithelial ovarian cancer treated with
NACT and interval debulking surgery at Memorial Sloan Kettering Cancer Center from 1 January 2008 through 1 May 2013. CGR was defined as no grossly visible disease at the completion of surgery.

Computed tomography image analysis

Quantities of skeletal muscle, VAT, and SAT were calculated from CT images using iNtuition software (v4.4, TeraRecon, Foster City, CA) by a single reader (J. V.) at three time points over the course of therapy—at diagnosis, following NACT, and following debulking surgery. The accuracy of CT tracing was verified by retracing a sample of the cohort at the end of the study. The average difference for all the measurements combined was 1%.

For each imaging data set, a 30-mm volumetric slab was analysed for the presence of skeletal muscle and adipose using a semi-automated technique. First, Hounsfield unit (HU) thresholds were set to −150 to −50 HU to identify adipose tissue and −29 to 150 HU to identify skeletal muscle, as previously described. A colour-coded map of voxels with the specified HU values was generated for six 5-mm thick CT levels. The non-muscular soft tissues (abdominopelvic viscera, large blood vessels, spinal cord, and portions of the bone marrow) were manually excluded by drawing a region of interest around the identified tissue region. The percentage of low-density muscle (HU < 0) was also recorded from each volumetric slab. SAT and VAT volumes were segmented using a similar semi-automated approach with iNutrition. An example of the semi-automated contouring is shown in Figure 1.

Statistical measures

Patient demographic and clinical characteristics were summarized using descriptive statistics. Body composition metrics (skeletal muscle, SAT, and VAT volumes) were summarized at each time point, and per-patient percentage differences were calculated. Comparisons of each metric from the prior time point (diagnosis vs. following NACT and following NACT vs. following debulking surgery) were conducted using the nonparametric Wilcoxon signed rank test.

Patients were classified by the achievement of CGR vs. any residual disease during debulking surgery. Comparisons between these groups and clinical factors were examined using the Wilcoxon rank sum test for continuous variables and the Fisher exact test for categorical variables. Subset analyses based on the BMI categories [non-overweight (BMI < 25 kg/m²), overweight (BMI = 25–29 kg/m²), and obese (BMI ≥ 30 kg/m²)] were also conducted. Within each BMI category, skeletal muscle volume was compared with surgical residual groups using the Wilcoxon rank sum test. Logistic regression was used to further examine the relationship between BMI and skeletal muscle with surgical outcome (CGR). Area under the receiver operating characteristic curve (AUC) was used to measure the predictive ability of either BMI or skeletal muscle on surgical outcome.

All significance tests were two sided, with a 5% level of significance. Analyses were performed with SAS 9.4 (SAS Institute Inc).
Results

One hundred fifty-four patients were evaluated over the study period; 52 were excluded for the following reasons: missing CT or clinical data, poor image quality (e.g. hardware scatter, motion, or windmill artefact), and atypical imaging parameters (unequal slice thickness or spacing), which were important for calculating volumetric data over multiple slices. The remaining 102 patients were included in the study, and their characteristics are described in Table 1. There was no difference between included and excluded subjects (Supporting Information, Table S1). The median age of the included subjects was 64 years (range, 38–90 years), and the median BMI was 25.7 kg/m$^2$ (range, 17.4–49.8 kg/m$^2$). The cohort was evenly split (50%) between stage IIIC and stage IV disease. Median preoperative CA-125 was 968 units/mL (range, 6–16,923 units/mL). Sixty patients (59%) achieved CGR following debulking surgery. The median day between completion of neoadjuvant therapy and interval debulking surgery was 29 days (Supporting Information, Table S2).

The median volumes of skeletal muscle, SAT, and VAT over the course of therapy (diagnosis, following NACT, and following debulking surgery) are shown in Table 2. Skeletal muscle volume was significantly reduced from diagnosis to following NACT ($P < 0.001$), whereas VAT and SAT volumes were unchanged. Following debulking surgery, which includes an omentectomy, VAT volume was significantly reduced ($P < 0.001$), whereas skeletal muscle and SAT volumes remained unchanged in comparison with the NACT scan.

To identify clinical parameters that are associated with CGR, patients were stratified based on CGR status (Table 3). Patients achieving CGR had significantly lower BMI ($P < 0.05$) and skeletal muscle volume at diagnosis ($P < 0.05$) and following NACT ($P < 0.05$). There was a trend for patients achieving CGR to have lower amounts of VAT ($P = 0.058$) as well. The association between skeletal muscle volume and CGR among different BMI subsets was also examined (Table 4). The significant association of skeletal muscle volume to CGR was found to be limited to patients with a BMI < 25 kg/m$^2$ ($P = 0.007$). In a univariate logistic regression analysis, BMI and the skeletal muscle volume following NACT were inversely correlated with CGR [OR for BMI: 0.926 (95% CI: 0.861, 0.996), and skeletal muscle: 0.990 (95% CI: 0.982, 0.998)]. To determine if skeletal muscle is a better predictor of CGR outcome, we calculated the AUC. The AUC for both BMI [AUC 0.617 (95% CI: 0.508–0.726)] and skeletal muscle volume [AUC 0.646 (95% CI: 0.537–0.755)] were similar. A bivariate logistic regression model was built to further investigate the relationship between BMI and CGR outcome after controlling for skeletal muscle. Based on the model, neither BMI ($P = 0.34$) nor skeletal muscle ($P = 0.112$) showed any significance.

Discussion

This is the first study to use radiologic measurements to identify trends in volumetric skeletal muscle and adipose tissue over the course of ovarian cancer treatment. We found that patients undergoing NACT for advanced ovarian cancer lost skeletal muscle volume; however, adiposity remained unchanged. This is in keeping with other published reports of patients with ovarian cancer undergoing chemotherapy and support the concerning deleterious effect of cytotoxic agents on skeletal muscle. This effect may be due
to the production of endogenous glucocorticoids, which elicits significant muscle atrophy in mice treated with cytotoxic chemotherapy.\textsuperscript{25}

We hypothesized that patients with ovarian cancer and higher VAT would have lower rates of CGR due to the greater area available in which disease can spread and elude detection during surgery. Previous studies using BMI as a surrogate for excess adiposity (including VAT) have shown that obese patients experience increased surgical blood loss and longer operating room time; however, no clear association with CGR has been detected.\textsuperscript{26,27} In the current study, we directly measured the amount of VAT and SAT in patients achieving CGR to those with any residual disease. Although we did detect a trend towards lower volumetric VAT in patients achieving CGR, this finding did not reach statistical significance. The lack of significance was influenced by the high variability in the distribution of VAT among subjects. Given the overlap in CT density between adipose tissue and malignant ascites, the identification of true VAT using imaging parameters may not be accurate in this setting.

Interestingly, we found that BMI and volumetric skeletal muscle were significantly lower in patients achieving CGR. A further exploration of these findings revealed that the association of CGR with skeletal muscle volume was limited to non-overweight patients (BMI <25 kg/m\textsuperscript{2}). One explanation for this finding is that in non-overweight patients, additional skeletal muscle makes disease detection and removal more difficult. With this knowledge, surgeons could better stratify patients’ risk and better strategize their operative plans to achieve CGR.

An important difference in our methodology from other body composition studies is the use of volumetric measurements instead of single axial slices. Volumetric measurement appears to be more accurate in assessing body composition. Studies estimating total volume of both visceral adipose and skeletal muscle found that more single axial slices on magnetic resonance imaging were needed to reach the same power of volumetric measurements.\textsuperscript{16,28} Although many body composition studies utilize single axial slices, volumetric measurements have been used in both non-small cell lung cancer and melanoma.\textsuperscript{29,30}

Our study is limited by its retrospective nature, which can lead to selection bias. An additional limitation is that we only examined patients undergoing NACT and interval debulking surgery, and these patients tend to have more disease or comorbidities that prevent them from undergoing primary debulking surgery. Furthermore, patients with CT images containing artefacts or incorrect image spacing were excluded. It is possible, albeit unlikely, that patients with images with these technical difficulties comprise a unique population that is underrepresented in our cohort. Despite these limitations, this study was able to reliably measure changes in skeletal muscle and adipose tissue volumes to uncover novel associations in patients achieving CGR.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.
Funding

Supported in part by NIH/NCI Grant R25 CA020449, NIH K08 CA230318, and the MSK Cancer Center Support Grant P30 CA008748.

References

1. Wild C, Stewart B. (n.d.) World cancer report. Report No.: 14.
2. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomized, controlled, non-inferiority trial. Lancet 2015 Jul;386:249–257. [PubMed: 26002111]
3. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010 Sep 2;363:943–953. [PubMed: 20818904]
4. Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 2002 Sep;11:822–828.
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003 Apr 24;348:1625–1638. [PubMed: 12711737]
6. Hess L, Barakat R, Tian C, Ozols R, Alberts D. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a gynecologic oncology group study. Gynecol Oncol 2007 Nov;107:260–265. [PubMed: 17675142]
7. McLemore MR, Miaskowski C, Aouizerat BE, Chen L, Dodd MJ. Epidemiological and genetic factors associated with ovarian cancer. Cancer Nurs 2009 Jul;32:281–288. [PubMed: 1944085]
8. Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Invest 2015 Jan;21:57–74.
9. Zhou Y, Chlebowski R, LaMonte MJ, Bea JW, Qi L, Wallace R, et al. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women’s Health Initiative. Gynecol Oncol 2014 Apr;133:4–10. [PubMed: 24680584]
10. Zhou Y, Chlebowski R, LaMonte MJ, Bea JW, Qi L, Wallace R, et al. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women’s Health Initiative. Gynecol Oncol 2014 Apr;133:4–10. [PubMed: 24680584]
11. Zhou Y, Chlebowski R, LaMonte MJ, Bea JW, Qi L, Wallace R, et al. Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women’s Health Initiative. Gynecol Oncol 2014 Apr;133:4–10. [PubMed: 24680584]
12. Nattenmüller J, Rom J, Buckner T, Arvin J, Bau B, Sohn C, et al. Visceral abdominal fat measured by computer tomography as a prognostic factor for gynecological malignancies? Oncotarget 2018 Mar 27;9:16330–16342. [PubMed: 29662648]
13. Zhang Y, Coletta AM, Allen PK, Parikh AM, Cox-Mattin M, Meyer LA, et al. Perirenal adiposity is associated with lower progression-free survival from ovarian cancer. Int J Gynecol Cancer 2018 Feb;28:285–292. [PubMed: 29309393]
14. Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008 Oct;33:997–1,006. [PubMed: 18923576]
15. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol Bethesda Md 1985 1998 Jul;85:115–122.
16. Shen W Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 2004 Dec 1;97:2333–2338. [PubMed: 15310748]
17. Gil KM, Frasure HE, Hopkins MP, Jenison EL, von Gruenigen VE. Body weight and composition changes in ovarian cancer patients during adjuvant chemotherapy. Gynecol Oncol 2006 Oct;103:247–252. [PubMed: 16690107]

18. Rutten IJG, van Dijk DPJ, Kruitwagen RFPM, Beets-Tan RGH, Olde Damink SWM, van Gorp T. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients: Loss of skeletal muscle in ovarian cancer. J Cachexia Sarcopenia Muscle 2016 Sep;7:458–466. [PubMed: 27030813]

19. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009 Mar 15;115:1234–1244. [PubMed: 19189349]

20. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002 Mar;20:1248–1259. [PubMed: 11870167]

21. Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013 Apr 20;31:1539–1547. [PubMed: 23530101]

22. Mueller JJ, Zhou QC, Iasonos A, O’Cearbhallil RE, Alvi FA, El Haraki A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol 2016 Mar;140:436–442. [PubMed: 26777991]

23. Chowdhury B, Sjöström L, Alpsten M, Kostanty J, Kvist H, Löfgren R. A multicompartment body composition technique based on computerized tomography. Int J Obes Relat Metab Disord J Int Assoc Study Obes 1994 Apr;18: 219–234.

24. Prado CMM, Baracos VE, Xiao J, Birdsell L, Stuyckens K, Park YC, et al. The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer. Appl Physiol Nutr Metab Physiol Appl Nutr Metab 2014 Jun;39:693–698.

25. Braun TP, Szumowski M, Levasseur PR, Grossberg AJ, Zhu X, Agarwal A, et al. Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle. PLoS ONE 2014;9:e106489. [PubMed: 25254959]

26. Matthews KS, Straughn JM, Kemper MK, Hoskins KE, Wang W, Rocconi RP. The effect of obesity on survival in patients with ovarian cancer. Gynecol Oncol 2009 Feb;112:389–393. [PubMed: 19062080]

27. Fotopoulou C, Richter R, Braicu E-I, Kuhberg M, Feldheiser A, Schefold JC, et al. Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking. Ann Surg Oncol 2011 Sep;18:2629–2637. [PubMed: 21394662]

28. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge M-P, Albu J, et al. Visceral adipose tissue: relations between single-slice areas and total volume. Am J Clin Nutr 2004 Aug:80:271–278. [PubMed: 15277145]

29. Goncalves MD, Taylor S, Halpenny DF, Schiwitzer E, Gandelman S, Jackson J, et al. Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer. Clin Radiol 2018 May;73:505. e1–505.e8.

30. Halpenny DF, Goncalves M, Schiwitzer E, Golia Pernicka J, Jackson J, Gandelman S, et al. Computed tomography-derived assessments of regional muscle volume: validating their use as predictors of whole body muscle volume in cancer patients. Br J Radiol 2018 Dec;91:20180451. [PubMed: 30179038]
Figure 1.
Semi-automated body composition analysis. (A) Example of an axial computed tomography slice at the level of L3. (B) Segmentation of body composition using iNtuition software. Green = skeletal muscle, blue = subcutaneous adipose tissue, red = visceral adipose tissue.
|                                | Median | Range      | No. of Patients | %   |
|--------------------------------|--------|------------|-----------------|-----|
| Age, years                     | 64     | 38–90      |                 |     |
| BMI, kg/m$^2$                  | 25.7   | 17.4–49.8  |                 |     |
| Days between scans             | 89     | 39–196     |                 |     |
| CA-125, units/mL               | 968    | 6–16,923   |                 |     |
| Stage (FIGO 1988)              |        |            |                 |     |
| IIIC                           | 51     | 50.0       |                 |     |
| IV                             | 48     | 47.1       |                 |     |
| IVB                            | 3      | 2.9        |                 |     |
| Medical comorbidities          |        |            |                 |     |
| Hypertension                   | 40     | 39.2       |                 |     |
| Pulmonary disease              | 18     | 17.6       |                 |     |
| Hypothyroid                    | 13     | 12.7       |                 |     |
| Diabetes                       | 12     | 11.8       |                 |     |
| Coronary artery disease        | 5      | 4.9        |                 |     |
| Complete Gross Resection       | 60     | 59.0       |                 |     |

BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics.
Changes in body composition during neoadjuvant and adjuvant therapy.

| Tissue volume median (range) | Diagnosis | Following NACT | % change | Following surgery | % change |
|-----------------------------|-----------|----------------|----------|-------------------|----------|
| Muscle (cm³)                | 352.5 (197–497) | 335.0 (233–473) * | -2.5 (-23.7–56.3) | 341.0 (222–552) | 1.4 (-19.9–87.1) |
| VAT (cm³)                   | 231.0 (13.4–982) | 207.0 (11.1–933) | -1.3 (-75–189.2) | 175.0 (24–878) ** | -10.1 (-60.4–184.7) |
| SAT (cm³)                   | 542.5 (45.8–1,564) | 583.0 (103–1,657) | -0.6 (-49–262.4) | 576.5 (18.6–1,662) | 0.7 (-94.7–250.6) |

NACT, neoadjuvant chemotherapy; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue.

* P < 0.001 between diagnosis and the scan following NACT.

** P < 0.001 between NACT scan and the scan following debulking surgery using the Wilcoxon rank sum test.
Table 3

Association of complete gross resection with clinical factors and skeletal muscle volumes

|                           | CGR     | Any residual | p  |
|---------------------------|---------|--------------|----|
| Total patients            | 60      | 42           |    |
| Age at diagnosis, years   | Median (Mean) 64 (61.5) | 65 (63.9)  | 0.266 |
|                           | Range   | 38–86        | 40–90 |
| BMI, kg/m²                | Median (Mean) 25.1 (25.8) | 27.1 (28.3) | 0.046 |
|                           | Range   | 17.4–40      | 19.4–49.8 |
| Stage                     | IIIC    | 28 (46.7%)   | 23 (54.8%) | 0.546 |
|                           | IV/IVB  | 32 (53.3%)   | 19 (45.2%) |
| Preop CA125 (1 missing), units/mL | Median (mean) 822 (1908.7) | 1,150 (1738.8) | 0.863 |
|                           | Range   | 6–16,923     | 34–10,500 |
| Comorbidities:            |         |              |    |
| Hypertension              | 24 (40%) | 16 (38.1%)   | 1   |
| Pulmonary disease         | 9 (15%)  | 9 (21.4%)    | 0.438 |
| Hypothyroid               | 7 (11.7%) | 6 (14.3%)    | 0.767 |
| Diabetes                  | 7 (11.7%) | 5 (11.9%)    | 1    |
| Coronary artery disease   | 5 (8.3%)  | 0 (0%)       | -    |
| Skeletal muscle volume, cm³|         |              |    |
| Diagnosis                 |         |              |    |
| Median (mean)             | 342 (343.6) | 366 (365.9) | 0.023 |
| Range                     | 238–497 | 197–497      |    |
| Following NACT            |         |              |    |
| Median (mean)             | 325 (330.1) | 353.5 (356.4) | 0.012 |
| Range                     | 241–461 | 233–473      |    |
| VAT volume, cm³           |         |              |    |
| Diagnosis                 |         |              |    |
| Median (mean)             | 215 (220.1) | 289 (290.7) | 0.058 |
| Range                     | 24–575  | 13.4–982     |    |
| Following NACT            |         |              |    |
| Median (mean)             | 195.5 (216.6) | 269.5 (285.3) | 0.078 |
| Range                     | 34–721  | 11.1–933     |    |
| SAT volume, cm³           |         |              |    |
| Diagnosis                 |         |              |    |
| Median (mean)             | 550 (608.1) | 530 (630.8) | 0.760 |
| Range                     | 45.8–1,478 | 96.5–1,564    |    |
| Following NACT            |         |              |    |
| Median (mean)             | 583 (608)  | 587 (631.5) | 0.801 |

*JCSM Clin Rep. Author manuscript; available in PMC 2021 September 03.*
|                  | CGR       | Any residual | \(p^a\) |
|------------------|-----------|--------------|---------|
| Range            | 107–1,657 | 103–1,433    |         |

BMI, body mass index; CGR, complete gross resection; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.

\(^a\) \(p\) values were obtained using the Wilcoxon rank sum test for continuous variables and Fisher exact test for categorical variables.
Table 4
Relationship between muscle volume and complete gross resection by body mass index

|                     | Following NACT | CGR      | Any residual | p<sup>a</sup> |
|---------------------|----------------|----------|--------------|---------------|
| **BMI < 25 kg/m<sup>2</sup> (n = 44)** |                |          |              |               |
| Muscle volume, cm<sup>3</sup> |                |          |              |               |
| Median (mean)       | 309 (306.7)    | 336 (342.7) | 0.007        |               |
| Range               | 241–377        | 298–473  |              |               |
| **BMI: 25–30 kg/m<sup>2</sup> (n = 31)** |                |          |              |               |
| Following NACT      |                |          |              |               |
| Muscle volume, cm<sup>3</sup> |                |          |              |               |
| Median (mean)       | 327 (330.9)    | 321 (337.1) | 1            |               |
| Range               | 266–420        | 233–471  |              |               |
| **BMI ≥ 30 kg/m<sup>2</sup> (n = 27)** |                |          |              |               |
| Following NACT      |                |          |              |               |
| Muscle volume, cm<sup>3</sup> |                |          |              |               |
| Median (mean)       | 371 (377.5)    | 397 (392.9) | 0.396        |               |
| Range               | 291–461        | 325–448  |              |               |

BMI, body mass index; CGR, complete gross resection; NACT, neoadjuvant chemotherapy.

<sup>a</sup>P values obtained using the Wilcoxon rank sum test.